Disease-related hepatic messenger RNA (mRNA) (mRNA)

Disease-related hepatic messenger RNA (mRNA) represents a class of therapeutic targets consisting of specific mRNA transcripts within hepatocytes that contribute to disease pathology. These targets are addressed using oligonucleotide-based therapies, including small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs), which are designed to reduce the expression of pathogenic proteins (Nature Reviews Drug Discovery, 2020). Most modern therapies in this class utilize N-acetylgalactosamine (GalNAc) conjugation to ensure targeted delivery to the liver via the asialoglycoprotein receptor (ASGPR) (Molecules, 2021). By inducing the degradation of the target mRNA through the RNA-induced silencing complex (RISC) or RNase H-mediated cleavage, these drugs provide a potent method for managing conditions like hypercholesterolemia, transthyretin-mediated amyloidosis, and primary hyperoxaluria (FDA, 2023). This target class is characterized by high specificity and a long duration of action, often requiring only infrequent dosing (Alnylam Pharmaceuticals, 2023). Safety considerations for these therapies include potential hepatotoxicity and off-target effects, though GalNAc conjugation has significantly improved the safety profile compared to earlier lipid nanoparticle delivery systems (PubMed, 2022).

Other names

Liver-specific mRNAHepatic transcriptsDisease-associated liver mRNA

RNA interference (RNAi) or antisense-mediated degradation of specific messenger RNA transcripts to prevent the translation of disease-causing proteins.